NCT04535141View on ClinicalTrials.gov

Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants

PHASE3CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

April 11, 2022

Study Completion Date

April 11, 2022

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Olanzapine 5 MG

It will be a de-identified pill created by investigational drug services at University of North Carolina

DRUG

Placebo

It will be a de-identified pill created by investigational drug services at University of North Carolina

Trial Locations (1)

27514

UNC Hospital, Chapel Hill

All Listed Sponsors
collaborator

University of North Carolina, Chapel Hill

OTHER

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT04535141 - Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants | Biotech Hunter | Biotech Hunter